Prescriber Scope of Practice for Weight Loss/GLP-1 in Pennsylvania

If you’re a psychiatrist or PMHNP watching the GLP-1 boom and wondering whether you can (or should) add weight management to your telehealth practice, you’re asking the right questions. The short answer: Yes, psychiatrists can legally prescribe weight-loss medications via telehealth in most states — but the regulatory landscape is messy, the economics are tricky, and your scope of practice matters more than you think.

Let’s cut through the confusion with what actually matters for your practice.

The Federal Telehealth Landscape: What the DEA Extension Means for You

Here’s where we stand as of 2026: The DEA has extended COVID-era telehealth flexibilities through December 31, 2026. This means you can currently prescribe controlled substances (including Schedule IV appetite suppressants like phentermine) via telemedicine to new patients without an initial in-person visit — federally speaking.

But — and this is critical — this is temporary. The DEA is working on permanent rules that will likely require special telemedicine registration or impose limits like initial 30-day supplies for certain controlled drugs. If you’re building a weight-loss telehealth practice around phentermine prescribing, you need a plan for when these flexibilities sunset.

The good news? GLP-1 agonists (semaglutide, tirzepatide) aren’t controlled substances. They’re freely prescribable via telehealth as long as you meet state prescribing standards. This is where the real opportunity sits — and where the regulatory headaches are actually more manageable.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Laws: The Real Gatekeepers

Federal rules are just the floor. State medical boards set the ceiling, and they vary wildly.

New York essentially says ‘not so fast’ — you need at least one in-person medical evaluation before prescribing any controlled substance to a patient (with very narrow exceptions like covering for a colleague). Starting someone on phentermine via telehealth alone? Illegal in NY as of 2025. But semaglutide? Totally fine via video visit.

Florida takes a different approach: telehealth prescribing of Schedule IV drugs like phentermine is allowed, but the state has strict obesity treatment rules. You must document BMI ≥30 (or ≥27 with comorbidities), obtain written informed consent, and re-evaluate patients every 3 months minimum. Skip these steps and you’re asking for a board complaint.

California is relatively permissive — telehealth exams satisfy the ‘appropriate prior examination’ requirement. But you must query the CURES PDMP database before prescribing any Schedule II–IV controlled substance and every 4 months thereafter. Plus, California’s corporate practice of medicine doctrine means you can’t just join any telehealth platform as an independent contractor; the business structure matters.

Texas allows telehealth prescribing with live video exams and requires coordination with the patient’s primary care provider (you’re supposed to send a report within 72 hours with patient consent). Pennsylvania and Illinois largely defer to federal standards but have their own PDMP requirements.

Bottom line: You need to verify each state’s current requirements before seeing patients there. Multi-state telehealth sounds great until you’re juggling five different sets of regulations.

Psychiatrist vs PMHNP: Scope of Practice Reality Check

As a psychiatrist (MD/DO), you have broad prescribing authority. You can legally prescribe FDA-approved weight-loss medications — GLP-1s, phentermine, whatever — even though obesity treatment isn’t your specialty. Medical boards don’t restrict MDs by specialty certification.

But here’s the catch: you’re held to the same standard of care as any physician treating obesity. That means:

• Documenting appropriate BMI and comorbidities
• Ruling out endocrine causes (thyroid issues, Cushing’s)
• Providing or coordinating nutrition/exercise counseling
• Monitoring for medication side effects and contraindications
• Following state-specific protocols (like Florida’s quarterly re-evaluations)

If you’re a psychiatrist who prescribes semaglutide to offset antipsychotic-induced weight gain? That’s squarely in your wheelhouse — you’re managing a complication of psychiatric treatment. But if you’re launching a standalone weight-loss practice, you’re competing with family medicine docs and obesity medicine specialists who do this all day. You better have your clinical protocols tight.

For PMHNPs and psychiatric NPs, the scope question is murkier. Your licensure is in mental health. Prescribing purely for obesity may be seen by state nursing boards as outside your training unless you’re working under physician collaboration or have additional certification.

In states like Texas and Florida, PMHNPs need a supervising physician to prescribe — and that physician should ideally have expertise in weight management, not just psychiatry. Some states allow NP independent practice after meeting experience requirements (California’s AB 890, Illinois’s Full Practice Authority), but even then, treating obesity as a psych NP raises scope questions.

Practical reality: Many psych NPs who want to do weight management either get additional obesity medicine training, partner with a family practice MD for supervision, or focus on the psych angle (treating binge eating disorder, addressing depression that contributes to weight gain) while collaborating with other providers for the metabolic piece.

The Economics: Why Patient Acquisition Cost Matters More Than You Think

Here’s where most providers get starry-eyed about telehealth weight loss and then slam into reality.

The promise: GLP-1 demand is through the roof. Patients are googling ‘semaglutide online’ constantly. Just hang out a shingle and print money, right?

The reality: Acquiring qualified psychiatric or weight-loss patients through DIY marketing typically costs $200–500+ per patient when you factor in:

• Agency or consultant fees for SEO and ad management
• Google Ads spend ($15–40+ per click for mental health and weight-loss keywords, with most clicks never converting to booked patients)
• Staff time to qualify leads and handle inquiries
• No-show rates from cold leads who aren’t truly committed
• Months of SEO investment before you see meaningful patient flow (6–12 months is standard)
• Failed campaigns where you burn budget testing different approaches

SEO takes 6–12 months of consistent investment before generating meaningful patient flow. Most solo providers don’t have the expertise, budget, or patience for this.

Directory listings like Psychology Today and Zocdoc can work, but you’re competing with hundreds of other providers on the same page. Zocdoc charges per booking ($35–100+), plus monthly subscription fees that add up fast. Psychology Today is pay-to-play for better visibility.

Let’s talk real numbers: If you’re spending $3,000–5,000/month on marketing (not unrealistic if you’re running Google Ads and paying for SEO), and you’re acquiring 10–15 new patients monthly, your cost per acquisition is in that $200–400 range. And that assumes your campaigns are working. Many providers burn through thousands testing ads that never convert.

The Klarity Alternative: Pay Only When You See Patients

This is where platforms like Klarity Health fundamentally change the economics.

Instead of gambling on marketing channels with uncertain ROI, Klarity uses a pay-per-appointment model. You pay a standard listing fee per new patient lead — similar to how Zocdoc works, but the key differences matter:

What you get:

• Pre-qualified patients already matched to your specialty and availability (not random clicks who ghost after the first message)
• No upfront marketing spend or monthly subscription fees eating into your cash flow
• No wasted ad budget on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs for video, EHR, etc.)
• Both insurance and cash-pay patient flow depending on what you accept
• You control your schedule — you only pay when you actually see patients

The economic logic: Instead of spending $3,000–5,000/month with uncertain results, you pay only when a qualified patient books with you. That’s guaranteed ROI vs gambling on marketing channels you may not understand.

For providers starting out or scaling up, this removes the risk entirely. You’re not betting your practice on whether your SEO guy knows what he’s doing or whether your Google Ads will ever convert. You’re paying for results.

Reality check: DIY marketing can eventually be cost-effective IF you have the budget, expertise, and patience to stick with it for 6–12 months. But for most providers — especially those starting out, working part-time, or scaling from solo to group practice — a platform that handles patient acquisition just makes sense.

State-Specific Considerations: Where Klarity Makes the Most Sense

The regulatory complexity of multi-state telehealth is another hidden cost of DIY practice.

If you want to see patients in New York, you need to either:

• See controlled-substance patients in person at least once (or coordinate with another provider who did)
• Stick to non-controlled GLP-1s and other weight-loss medications

Florida requires quarterly re-evaluations and written informed consent forms for obesity treatment. You need workflows to track this or you’ll miss follow-ups and violate state rules.

California demands PDMP checks every 4 months for ongoing controlled substance therapy and has strict corporate practice rules that affect how you can contract with platforms.

Texas expects you to coordinate with patients’ primary care providers and send reports within 72 hours.

Pennsylvania and Illinois are more flexible but still have their own PDMP and prescribing rules.

Platforms like Klarity build state-specific compliance into their workflows — the consent forms are pre-loaded, the follow-up scheduling is automated, the PDMP integration is there. When you’re juggling five states’ worth of regulations, that infrastructure is worth something real.

Practical Steps: Making Weight Loss Telehealth Work

If you’re serious about adding weight management to your practice (whether through Klarity or independently), here’s what you need:

1. Get your clinical protocols tight

Weight-loss prescribing isn’t just writing for semaglutide and calling it a day. You need:

• Initial evaluation protocols (BMI calculation, medical history, contraindication screening)
• Informed consent processes that meet state requirements
• Monitoring schedules for side effects, dose titration, and outcome tracking
• Referral pathways for patients who need additional support (nutrition, endocrinology, cardiology)

2. Understand state-specific requirements where you’re licensed

Pull up your state medical board’s rules on:

• Telehealth prescribing standards (in-person exam requirements, modalities allowed)
• Obesity treatment regulations (some states have specific BMI thresholds, follow-up schedules, consent requirements)
• PDMP query requirements and documentation
• NP/PA supervision rules if you’re hiring or partnering with advanced practice providers

3. Build compliance into your workflows from day one

This means:

• Documenting telehealth consent in the first encounter
• Setting up automated PDMP queries before prescribing controlled substances
• Creating templates for obesity treatment notes that capture required elements (BMI, comorbidities, lifestyle counseling provided, etc.)
• Scheduling follow-up appointments at state-mandated intervals (3 months in Florida, more frequent in other states)

4. Consider the business model

Are you:

• Building a standalone weight-loss practice (high marketing costs, long ramp-up, potential for scale)?
• Adding weight management as an adjunct to psychiatric practice (leverages existing patient relationships, lower patient acquisition cost, but limited scalability)?
• Partnering with a platform like Klarity to handle patient acquisition and infrastructure (lower risk, faster ramp-up, less control over branding)?

Each has tradeoffs. Most providers starting out underestimate patient acquisition costs and overestimate how quickly they can scale independently.

The Bottom Line: Know Your Numbers, Know Your Regulations, Pick Your Model

Can you prescribe weight-loss medications via telehealth as a psychiatrist? Yes, in most states, for both controlled (phentermine) and non-controlled (GLP-1) medications — subject to state-specific rules.

Should you? That depends on whether you’re prepared to:

• Meet the clinical standard of care for obesity treatment (which goes beyond psychiatric prescribing)
• Navigate state-by-state regulatory variations
• Either invest heavily in patient acquisition marketing OR partner with a platform that handles it

The GLP-1 weight-loss boom is real. Patient demand is high. But turning that demand into a sustainable telehealth practice requires understanding both the regulatory landscape and the business economics.

If you’re treating weight gain as a side effect of psychiatric medications in your existing patients? You’re already in your lane — just tighten up your protocols to meet state requirements.

If you’re launching a dedicated weight-loss practice? Be honest about patient acquisition costs. For most providers, platforms like Klarity that use a pay-per-appointment model make more economic sense than gambling thousands on marketing channels with uncertain ROI.

Ready to explore how Klarity’s provider network could fit your practice? The platform is designed specifically to solve the patient acquisition and compliance infrastructure challenges that make independent telehealth difficult. You focus on clinical care; Klarity handles the rest — and you only pay when you see patients.

Frequently Asked Questions

Can psychiatrists legally prescribe GLP-1 medications like Ozempic or Wegovy for weight loss?

Yes. As fully licensed physicians, psychiatrists have the legal authority to prescribe any FDA-approved medication, including GLP-1 agonists for weight management. However, you must meet the same standard of care as any physician treating obesity: documenting appropriate BMI (≥30 or ≥27 with comorbidities), ruling out contraindications, providing lifestyle counseling, and monitoring for side effects. GLP-1s aren’t controlled substances, so they don’t face the DEA’s telehealth prescribing restrictions — just state-specific medical practice standards.

Do I need an in-person visit before prescribing weight-loss medications via telehealth?

It depends on your state and the medication. Under current federal rules (extended through December 31, 2026), no in-person visit is required for controlled substances like phentermine when prescribing via telehealth. However, New York requires at least one in-person evaluation before prescribing any controlled substance (with narrow exceptions). Other states like Florida, Texas, and California allow telehealth-only evaluations as long as you conduct an appropriate exam via live video and meet standard-of-care requirements. For non-controlled GLP-1 medications, most states accept telehealth evaluations without in-person visits.

Can PMHNPs prescribe weight-loss medications, or is that outside their scope of practice?

PMHNPs’ scope is defined by their mental health training and certification. Prescribing solely for obesity may be viewed by state nursing boards as outside your scope unless done under physician supervision or with additional training. In states requiring NP collaboration (like Texas and Florida), you’d need a supervising physician with appropriate expertise (family medicine or endocrinology, not just psychiatry). States with NP independent practice (like California after AB 890 or Illinois with Full Practice Authority) allow experienced NPs to practice independently, but you’re still expected to stay within your competency area. Many psych NPs who do weight management either get additional obesity medicine certification or focus on the mental health aspects (binge eating disorder, depression contributing to weight gain) while collaborating with other providers for the metabolic piece.

What are the actual costs of acquiring weight-loss patients through DIY marketing?

Realistic patient acquisition costs through DIY marketing (SEO, Google Ads, directories) typically run $200–500+ per booked patient when you account for all costs: agency/consultant fees, ad spend and optimization, staff time to qualify leads, no-show rates, and months of investment before results. Google Ads for weight-loss keywords cost $15–40+ per click, and most clicks don’t convert to appointments. SEO takes 6–12 months of consistent investment before generating meaningful patient flow. Directory listings like Psychology Today and Zocdoc charge monthly fees plus booking fees ($35–100+), and you’re competing with hundreds of other providers. Many solo providers spend $3,000–5,000/month on marketing with uncertain results.

How does Klarity’s pay-per-appointment model compare to traditional patient acquisition?

Instead of gambling on marketing channels with upfront costs and uncertain ROI, Klarity charges a standard listing fee per new patient lead. You get pre-qualified patients already matched to your specialty and availability, no monthly subscription fees, built-in telehealth infrastructure, and both insurance and cash-pay patient flow. You only pay when you actually see patients — guaranteed ROI vs spending thousands testing marketing campaigns that may never convert. For providers starting out or scaling up, this removes the risk of burning budget on ads that don’t work or waiting 6–12 months for SEO to generate patients.

What state-specific regulations do I need to know for telehealth weight-loss prescribing?

Key state variations include:

• New York: In-person exam required before prescribing controlled substances; must check PMP within 24 hours before prescribing; all prescriptions must be e-prescribed
• Florida: Quarterly re-evaluations required for obesity medications; written informed consent mandatory; must provide ‘Weight-Loss Consumer Bill of Rights’; no teleprescribing of Schedule II drugs (but phentermine is Schedule IV, so allowed)
• California: Must check CURES PDMP before first fill and every 4 months for controlled substances; documented telehealth consent required; corporate practice of medicine rules restrict business structures
• Texas: Must send report to patient’s PCP within 72 hours (with consent); check Texas PMP for controlled substances; NPs/PAs need prescriptive authority agreements
• Pennsylvania and Illinois: Defer largely to federal standards but have specific PDMP requirements for opioids/benzodiazepines

What clinical protocols do I need for compliant weight-loss prescribing?

Essential protocols include: initial evaluation documenting BMI, medical history, contraindication screening, and ruling out endocrine causes; informed consent processes meeting state requirements (written consent in Florida, documented consent in California); monitoring schedules for side effects, dose titration, and outcomes; follow-up intervals meeting state mandates (every 3 months minimum in Florida); PDMP queries before prescribing controlled substances; documentation of lifestyle counseling (nutrition, exercise); referral pathways for patients needing additional support. State medical boards expect you to follow the same comprehensive care standards as obesity medicine specialists, even if that’s not your primary specialty.

Is the telehealth weight-loss market oversaturated, or is there still opportunity?

Demand for GLP-1 medications and weight management remains extremely high — patient searches for ‘semaglutide online’ and ‘Ozempic telehealth’ are at record levels. However, competition is increasing as more providers and platforms enter the space. The key differentiators are: clinical quality and comprehensive care (not just prescription mills), efficient patient acquisition economics, multi-state licensure and compliance infrastructure, and coordination with patients’ existing healthcare providers. Primary care physicians surveyed in 2025 expressed concerns about telehealth weight-loss prescribers’ quality — over half warn patients about risks of using these services. This creates opportunity for providers who do it right: thorough evaluations, appropriate monitoring, lifestyle counseling, and care coordination. The market is big enough for quality providers but increasingly unfriendly to shortcuts.

Citations and Sources

1. U.S. Department of Health & Human Services. ‘HHS and DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press Release, January 2, 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (Florida Telehealth Act). Effective 2019 (accessed November 2025). https://florida.public.law/statutes/fla.stat.456.47

3. Florida Administrative Code 64B8-9.012 – Standards for the Prescription of Drugs to Treat Obesity. Effective August 8, 2022. https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

4. Goodwin Procter LLP. ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs.’ Client Alert, March 30, 2024. https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. McDermott Will & Emery LLP. ‘Weight-Loss Programs in Florida: State Law Considerations for GLP-1 Telehealth Providers.’ Blog post, September 29, 2023. https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/

6. Medical Director Compliance Consulting. ‘California Weight Loss Clinic & Telehealth Compliance Guide (2025).’ 2025. https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/

7. Medical Director Compliance Consulting. ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025).’ 2025. https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

8. New York Codes, Rules and Regulations Title 10, §80.63 – Prescribing of Controlled Substances. Amended May 2025. https://www.law.cornell.edu/regulations/new-york/10-NYCRR-80.63

9. Fierce Healthcare. Landi, Heather. ‘Primary care doctors concerned about telehealth GLP-1 boom: survey.’ February 13, 2025. https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey

10. California Medical Association. ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal.’ News release, December 2, 2025. https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

11. Center for Connected Health Policy. ‘State Telehealth Policies for Online Prescribing.’ Updated November 21, 2025. https://www.cchpca.org/topic/online-prescribing/

12. Pennsylvania Department of Health. ‘Prescription Drug Monitoring Program FAQs.’ Accessed 2025. https://www.pa.gov/agencies/health/programs/opioids/prescribers-and-providers/prescribing-guidelines.html

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated